Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGIR | P43119 | 19/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517561 | 1.00 | PLG (0.50) | PLGPLATLMNAPTGIRPTGDR | |
| SCHEMBL1118701 | 1.00 | PLG (0.50) | PLGPLATLMNAPTGIRPTGDR | |
| SCHEMBL937100 | 0.89 | — | — | |
| Formic Acid SCHEMBL28279122 | 0.82 | PTGIR (0.50) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL2374517 | 0.82 | PTGIR (0.50) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL2374514 | 0.82 | PTGIR (0.50) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL6345787 | 0.81 | PTGIR (0.49) | LMNAPTGIRPTGDRPTGER1PTGER4 | |
| SCHEMBL16888038 | 0.80 | PTGIR (0.49) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL9132825 | 0.79 | LMNA (0.53) | LMNAPTGIRPTGDRPTGER1PTGER4 | |
| SCHEMBL2346158 | 0.79 | LMNA (0.53) | LMNAPTGIRPTGDRPTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3884934-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |